Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Read more: Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR InhibitorsVariational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Read more: Update: Advancing CNS-penetrant ATR inhibitors with Enki™Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Read more: Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug DiscoveryVariational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Read more: Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AIFollowing their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Redefining the unit economics of drug discovery for better patient outcomes
With an estimated 10⁶⁰ possible drug-like molecules, the chemical space is unimaginably large. And yet, drug discovery has only scratched its surface.
At Variational AI, we believe that the future of drug discovery lies not in screening molecules but in generating them. Using generative AI, we create novel, synthesizable small molecules optimized across multiple objectives such as potency, selectivity, and safety, without relying on massive screening libraries.
Our platform, Enki™, enables rapid exploration of uncharted chemical space — transforming the cost, speed, and scope of small molecule drug discovery, starting with oncology.
A simple workflow made to fit with your discovery process
From target product profile to synthesis-ready leads in weeks. Enki™ generates and optimizes novel compounds to meet selectivity, potency, toxicity, and pharmacokinetic goals.
1. Define the preclinical target product profile (TPP)
Specify the On/Off-targets and physico-chemical properties of the molecules as input for Enki™ generative AI.
2. Enki™ generates compounds
Enki™ generates novel and diverse structures that meet the defined TPP.
3. Make your selection
Pick compounds you want to synthesize and test. Enki™ can also perform hyper-efficient lead optimization while constrained to a defined scaffold.
Designed for early discovery
Purpose-built for early discovery, Enki™ helps generate first- and best-in-class compounds across multiple therapeutic areas
Generative AI, not screening
We generate new molecules de novo — freeing you from reliance on experimental or virtual libraries.
Multi-objective optimization
Enki™ simultaneously optimizes for more than 50 physico-chemical properties reflecting potency, selectivity, toxicity, PK, synthesizability and ADME.
Transforming drug discovery with AI
At Variational AI, we bring together machine learning researchers, chemists, and biotech professionals united by one mission: transforming early drug discovery with generative AI. Our cross-disciplinary team is always looking for new talents to push the boundaries of science and technology alongside us.
In the Press
23–26 June, 2026
Hotel Nelligan
Variational AI at CCG’s North American UGM & Conference 2026
Read more: Variational AI at CCG’s North American UGM & Conference 2026Variational AI will be at the CCG North American UGM & Conference in Montreal (June 23–26, 2026). Join Alex Perryman’s scientific presentation on June 25 on how MOE supported multiple… Learn More about Variational AI at CCG’s North American UGM & Conference 2026
25–25 February, 2026
Vancouver Convention Center West – Summit Level 3
Variational AI at LSBC’s 11th Annual Access to Innovation
Read more: Variational AI at LSBC’s 11th Annual Access to InnovationVariational AI will be at Life Sciences BC’s 11th Annual Access to Innovation on February 25, 2026 in Vancouver. Connect with our team to discuss how generative AI is changing… Learn More about Variational AI at LSBC’s 11th Annual Access to Innovation
18–20 March, 2026
Boston, MA
Variational AI at AI Convergence: Small Molecule Discovery Summit 2026
Read more: Variational AI at AI Convergence: Small Molecule Discovery Summit 2026Variational AI is excited to participate in the inaugural AI Convergence: Small Molecule Discovery Summit in Boston, bringing together leaders at the intersection of AI/ML, computational chemistry, and medicinal chemistry.… Learn More about Variational AI at AI Convergence: Small Molecule Discovery Summit 2026
